Study of A166 in Patients With Relapsed / Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Status: Active

Description

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

Eligibility Criteria

Inclusion Criteria

  • Inclusion Criteria: Phase I Patients must meet the following criteria for inclusion into the study: 1. Patients must be able to provide documented voluntary informed consent. 2. Male or female patient ≥ 18 years. 3. Histologically documented, incurable, locally advanced or metastatic cancer. 4. Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease. HER2 expressing is defined in this protocol as HER2 expression of ≥ 1+ determined by validated IHC. 5. Patients should have no available therapy likely to convey clinical benefit. 6. Granulocyte count ≥ 1,500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9 g/dL. 7. Serum bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN). 8. Creatinine clearance ≥ 50 mL/min calculated by Cockroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed. 9. ECOG Performance Status ≤ 1. 10. Women of childbearing potential and men must agree to use an approved method of birth control (e.g., hormonal, barrier) while receiving study drug, and for at least 7 months after the last dose of study drug. Women are excluded from birth control if they had had tubal ligation or a hysterectomy. 11. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo. Phase II Patients must meet the following criteria for inclusion into the study: 1. Patients must be able to provide documented voluntary informed consent. 2. Male or female patient ≥ 18 years. 3. Histologically documented, incurable, locally advanced or metastatic cancer. 4. Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease. HER2 expressing is defined in this protocol as HER2 expression of ≥ 1+ determined by validated IHC. 5. Regarding previous therapy: 5.1. Cohort 1: HER2 positive (IHC 2+ with FISH confirmation and Immunohistochemistry (IHC 3+) breast cancer: patients should have progressed after at least 2 previous HER2 directed regimens in metastatic disease with approved therapies. 5.2. Cohort 2: HER2 positive (IHC 2+ with FISH confirmation and IHC 3+) gastric cancer: patients should have progressed after at least 1 previous HER2 directed regimens in metastatic disease with approved therapies. 5.3. Cohort 3: HER2 low expressing (IHC 1+ and IHC 2+ without FISH confirmation) breast cancer: patients should have no available therapy likely to convey clinical benefit. 5.4. Cohort 4: all cancers other than breast cancer with low HER2 expression (IHC 1+ and IHC 2+ without FISH confirmation) and HER2 positive (IHC 2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer: patients should have no available therapy likely to convey clinical benefit. 6. Granulocyte count ≥ 1,500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9 g/dL. 7. Serum bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN). 8. Creatinine clearance ≥ 50 mL/min calculated by Cockroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed. 9. ECOG Performance Status ≤ 1. 10. Women of childbearing potential and men must agree to use an approved method of birth control (e.g., hormonal, barrier) while receiving study drug, and for at least 7 months after the last dose of study drug. Women are excluded from birth control if they had had tubal ligation or a hysterectomy. 11. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo. Exclusion Criteria: Phase I: 1. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia). 2. History of Grade ≥ 3 hypersensitivity reaction to trastuzumab. 3. History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued. 4. Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug. 5. Require supplemental oxygen for daily activities. 6. Documented Grade ≥ 2 peripheral neuropathy. 7. Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks of first infusion of study drug. 8. Any experimental therapy within 4 weeks of first infusion of study drug. 9. Any major surgical procedure within 4 weeks of first infusion of study drug. 10. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis. Patients who have positive hepatitis B virus test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti hepatitis B core protein, and positive antibody to the HBsAg (anti-HBs) are not excluded. 11. Have known prior positive test results for human immunodeficiency virus. 12. Uncontrolled hypertension or diabetes. 13. Pregnancy or lactation. 14. Resting corrected QT interval (QTc) > 470 ms at baseline. 15. Left ventricular ejection fraction (LVEF) < 45% determined by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. 16. Prior cumulative doxorubicin dose of > 360 mg/m2 or equivalent. Phase II: 1. Any patient who was treated in the Phase I part of this study. 2. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia). 3. History of Grade ≥ 3 hypersensitivity reaction to trastuzumab. 4. History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued. 5. Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug. 6. Require supplemental oxygen for daily activities. 7. Documented Grade ≥ 2 peripheral neuropathy. 8. Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks of first infusion of study drug. 9. Any experimental therapy within 4 weeks of first infusion of study drug. 10. Any major surgical procedure within 4 weeks of first infusion of study drug. 11. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis. Patients who have positive hepatitis B virus test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti hepatitis B core protein, and positive antibody to the HBsAg (anti-HBs) are not excluded. 12. Have known prior positive test results for human immunodeficiency virus. 13. Uncontrolled hypertension or diabetes. 14. Pregnancy or lactation. 15. Resting QTc > 470 ms at baseline. 16. LVEF < 45% determined by ECHO or MUGA scan. 17. Prior cumulative doxorubicin dose of > 360 mg/m2 or equivalent.

Locations & Contacts

Massachusetts

Boston
Beth Israel Deaconess Medical Center
Status: Active
Contact: Cassandra L. Cruz
Phone: 617-975-7411
Email: clcruz@bidmc.harvard.edu

Michigan

Detroit
Wayne State University / Karmanos Cancer Institute
Status: Active
Name Not Available

Oklahoma

Oklahoma City
University of Oklahoma Health Sciences Center
Status: Active
Name Not Available

Texas

Houston
M D Anderson Cancer Center
Status: Active
Contact: Yunfang Jiang
Phone: 713-794-1751
Email: yjiang@mdanderson.org

Trial Objectives and Outline

This is an open-label, Phase I-II, first-in-human (FIH) study for A166 as monotherapy in HER2-expressing patients who progressed on or did not respond to available standard therapies. Patients enrolled in this Phase III study must have documented HER2 positivity defined as positive on in situ hybridization (ISH) or next-generation sequencing (NGS) or HER2 expression, defined as at least 1+ by validated immunohistochemistry (IHC) test. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have ceased to provide clinical benefit for their disease. Patients will receive study drug as a single IV infusion at the prescribed dose level in each treatment cycle. Cycles will continue until disease progression or unacceptable toxicity. The study is divided into 2 parts (Phase I and Phase II).

Trial Phase & Type

Trial Phase

Phase I/II

Trial Type

Treatment

Lead Organization

Lead Organization
Klus Pharma Inc.

Trial IDs

Primary ID KlusPharma
Secondary IDs NCI-2018-02801
Clinicaltrials.gov ID NCT03602079